Effects of drug procurement under cap price policy in Sanming

doi:10.5246/jcps.2018.11.080

Journal of Chinese Pharmaceutical Sciences ›› 2018, Vol. 27 ›› Issue (11): 799-804.DOI: 10.5246/jcps.2018.11.080

• Drug administration and clinical pharmacy column • Previous Articles Next Articles

Effects of drug procurement under cap price policy in Sanming

Ting Yin, Bin Jiang^*

Department of Administrative and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China

Received:2018-08-08 Revised:2018-10-27 Online:2018-11-28 Published:2018-11-03
Contact: Tel.: +86-13601100121, E-mail: binjiang@bjmu.edu.cn
Supported by:
China Medical Board (Grant No. 15-221).

Abstract

Abstract:

To study the effects of drug procurement under cap price policy (DPUCP) in Sanming, changes in drug category, price, availability and corporate structure were analyzed using purchasing data of the 7^th and 8^th centralized drug procurement in Fujian Province and the 1^st drug procurement under cap price in Sanming, and a field investigation was conducted. (1) The amounts of bid-winning drugs and pharmaceutical makers decreased sharply, leading to optimization of drug category and supplier structure. (2) The procurement could meet clinical demands, though a small percentage of drugs were out of stock. (3) Drug prices fell in general, with 10% decline in domestic drugs with a unit package price over RMB 5 yuan, a slight price reduction in imported drugs, and some price increase in cheap domestic drugs with a unit package price under RMB 3 yuan. DPUCP policy in Sanming optimized procurement drug category and supplier structure, reduced price, and improved industrial structure. However, problems still existed, such as shortage of some drugs and little price reduction in imported and brand-name drugs.

Key words: Drug procurement, Drug bidding, Policy effect, Sanming

CLC Number:

R951

Supporting:

Ting Yin, Bin Jiang. Effects of drug procurement under cap price policy in Sanming[J]. Journal of Chinese Pharmaceutical Sciences, 2018, 27(11): 799-804.

References

[1] Sanming Leading Group for Deepening Healthcare Reform. 2013. This article can be found online at http://www.sm.gov.cn/fw/ggfwpt/ylws/zcfg/201403/t20140306_300775.htm.

[2] Chen, C.; Li, B.; Yang, D.S.; Jiang, B. Implementation of NFS (2012) in Qingdao: from the Perspective of Public Policy Implementation. Chin. Pharm. Sci. 2016, 25, 695–699.

[3] Gan, J.; Wang, S.L.; Deng, Z.G.; Pu, C. Effect, Existing Problems and Suggestions on the Implementation of Drug Purchasing System Based on the Investigation of Primary Medical and Health Institutions in Chongqing City. Chin. Pharm. 2016, 27, 2884–2886.

[4] Gao, C.S.; Shi, Y.P. The Impacts of Medicine Centralized Bidding and Purchasing Policy: An Empirical Study on the Relationship between the Bid Winners and the Bidden Prices. Chin. J. Health. Policy. 2015, 8, 7–13.

[5] Guo, J. The Research about the Quality and Price of the Drug Centralised Bid Procurement in Shanxi Province. MPH. Shanxi Medical University. 2010.

[6] Yang, Z.; Zhao, Y.; Chen, J.; Yu, J.X.; Lan, J.W.; Jiang, B. Investigating on the Effects of National Essential Medicine Policy on Primary Care Facilities in Hebei Province: A Case Study. Chin. Pharm. Sci. 2015, 24, 683–689.

[7] Hu, M.; Zeng, Y.; Yang, J.B.; Wu, P. A Survey of Drug Supply Organizations in Rural Areas in Four Provinces of China. Chin. Pharm. Sci. 2005, 14, 237–241.

[8] Wu, L.N.; Fang, Y.; Yang, C.J.; Shen, Q.; Chang, J.; Zhu, W.W.; Ye, D.; Lv, B.; Yang, S.A Review of Research on Drug Shortages in China. Chin. Pharm. Affa. 2016, 5, 458–465.

[9] Ma, J.C.; Luo, Z.W.; Liu, Z.L.; Chen, J.S. Survey on the Shortage of Drugs in Medical Institutions of Six Regions in China Chin. Hosp. Pharm. J. 2014, 34, 229–232.

[10] Fujian Provicial Medical Security Management Committee Office. 2017. This article can be found online at http://www.fjylbz.gov.cn/med/rest/med/postDetailed.htm? postId=c876c77b-5223-4f4f-9f4c-37125d6f391d&type= zwdwgk.

[11] Tang, X. Research on the Development Path of China’s Drug Procurement Model. MPA. Southwest University. 2015.

[12] Wu, S.H.; Wu, Q.Y. Frequent Drug Shortages Forcing Medical Price Reform. Chin. Pharms. 2016, 25, 1–3.

[13] Ying, Y.Z. Report on the Reform of Public Hospitals in Sanming City. Health. Econom. Res. 2014, 10, 30–33.

[14] Huang, J. Drug Price Management and Countermeasures in China since the New Medical Reform. MPA. Fudan University. 2014.

[15] Huang, X.W.; Lv, Y.L.; Shi, L.W.; Jiang, B. Exploratory research on drug safety in China. Chin. Pharm. Sci. 2009, 18, 278–282.

[16] Yu, S.S.; Zhang, Z.F.; Li, Z.Q. Investigation and Countermeasures to the Current Status of the Generics Quality Consistency Evaluation. Chin. J. Clin. Pharm. Therap. 2015, 20, 118–120.

Effects of drug procurement under cap price policy in Sanming

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 3

Recommended Articles

Metrics

Comments

[1]	Aichen Yu, Mengyuan Fu, Bingyu Ni, Chunxia Man, Jingyuan Zhang, Huajie Hu, Ye Tian, Yue Zhou, Sheng Han, Xiaodong Guan Guan, Luwen Shi. Trends on medicine use in county public hospitals in Sanming, China from 2011 to 2017 [J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(3): 218-223.
[2]	Ruojing Zhou, Bin Jiang. Effects of drug purchasing under joint price caps policy in Fujian Province, China [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(2): 139-152.
[3]	Zhao Yang, Yile Zhao, Jing Chen, Jiaxuan Yu, Jianwen Lan, Bin Jiang. Investigating on the effects of national essential medicine policy on primary care facilities in Hebei province: a case study [J]. Journal of Chinese Pharmaceutical Sciences, 2015, 24(10): 683-689.